Stimulation of the human CTP:Phosphoethanolamine cytidylyltransferase gene by early growth response protein 1

Journal of Lipid Research

Volumn 49, Issue 10, 2008, Pages 2197-2211

  Zhu, Lin ^a   Johnson, Christa ^a   Bakovic, Marica ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

EGR1; NF B; PCYT2; Phosphatidylethanolamine; Phospholipids

Indexed keywords

CYTIDINE TRIPHOSPHATE; EARLY GROWTH RESPONSE FACTOR 1; ETHANOLAMINE PHOSPHATE CYTIDYLYLTRANSFERASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; BREAST EPITHELIUM; CELL STRAIN MCF 7; CONTROLLED STUDY; ENZYME ACTIVITY; GENE ACTIVATION; GENE EXPRESSION; GENE LOCATION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FUNCTION;

CELL LINE, TUMOR; CYTIDINE DIPHOSPHATE; EARLY GROWTH RESPONSE PROTEIN 1; ETHANOLAMINES; GC RICH SEQUENCE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; INTRACELLULAR SPACE; NF-KAPPA B; NFI TRANSCRIPTION FACTORS; PHOSPHATIDYLETHANOLAMINES; PROMOTER REGIONS, GENETIC; RNA NUCLEOTIDYLTRANSFERASES;

EID: 67649742844     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800259-JLR200     Document Type: Article

References (48)

1. Bakovic, M., M. D. Fullerton, and V. Michel. 2007. Metabolic and molecular aspects of ethanolamine phospholipid biosynthesis: the role of CTP:phosphoethanolamine cytidylyltransferase (Pcyt2). Biochem. Cell Biol. 85: 283-300.
2. Emoto, K., T. Kobayashi, A. Yamaji, H. Aizawa, I. Yahara, K. Inoue, and M. Umeda. 1996. Redistribution of phosphatidylethanolamine at the cleavage furrow of dividing cells during cytokinesis. Proc. Natl. Acad. Sci. USA. 93: 12867-12872.
3. Emoto, K., N. Toyama-Sorimachi, H. Karasuyama, K. Inoue, and M. Umeda. 1997. Exposure of phosphatidylethanolamine on the surface of apoptotic cells. Exp. Cell Res. 232: 430-434.
4. Kobayashi, T., and R. E. Pagano. 1989. Lipid transport during mitosis. Alternative pathways for delivery of newly synthesized lipids to the cell surface. J. Biol. Chem. 264: 5966-5973.
5. Kanfer, J. N. 1980. The base exchange enzymes and phospholipase D of mammalian tissue. Can. J. Biochem. 58: 1370-1380.
6. Lee, T. 1998. Biosynthesis and possible biological functions of plasmalogens. Biochim. Biophys. Acta. 1394: 129-145.
7. Sundler, R., and B. Akesson. 1975. Regulation of phospholipid biosynthesis in isolated rat hepatocytes. Effect of different substrates. J. Biol. Chem. 250: 3359-3367.
8. Kennedy, E. P., and S. B. Weiss. 1956. The function of cytidine coenzymes in the biosynthesis of phospholipides. J. Biol. Chem. 222: 193-214.
9. Poloumienko, A., A. Cote, A. T. Quee, L. Zhu, and M. Bakovic. 2004. Genomic organization and differential splicing of the mouse and human Pcyt2 genes. Gene. 325: 145-155.
10. Tie, A., and M. Bakovic. 2007. Alternative splicing of CTP:phosphoethanolamine cytidylyltransferase produces two isoforms that differ in catalytic properties. J. Lipid Res. 48: 2172-2181.
11. Fullerton, M. D., F. Hakimuddin, and M. Bakovic. 2007. Developmental and metabolic effects of disruption of the mouse CTP: phosphoethanolamine cytidylyltransferase gene (Pcyt2). Mol. Cell. Biol. 27: 3327-3336.
12. Orsetti, B., F. Courjal, M. Cuny, C. Rodriguez, and C. Theillet. 1999. 17q21-q25 aberrations in breast cancer: combined allelotyping and CGH analysis reveals 5 regions of allelic imbalance among which two correspond to DNA amplification. Oncogene. 18: 6262-6270.
13. Smith, T. A., C. Bush, C. Jameson, J. C. Titley, M. O. Leach, D. E. Wilman, and V. R. McCready. 1993. Phospholipid metabolites, prognosis and proliferation in human breast carcinoma. NMR Biomed. 6: 318-323.
14. Podo, F. 1999. Tumour phospholipid metabolism. NMR Biomed. 12: 413-439.
15. Johnson, C. M., Z. Yuan, and M. Bakovic. 2005. Characterization of transcription factors and cis-acting elements that regulate human CTP:phosphoethanolamine cytidylyltransferase (Pcyt2). Biochim. Biophys. Acta. 1735: 230-235.
16. Haffner, M. C., C. Berlato, and W. Doppler. 2006. Exploiting our knowledge of NF-kappaB signaling for the treatment of mammary cancer. J. Mammary Gland Biol. Neoplasia. 11: 63-73.
17. Thiel, G., and G. Cibelli. 2002. Regulation of life and death by the zinc finger transcription factor Egr-1. J. Cell. Physiol. 193: 287-292.
18. Huang, R. P., Y. Fan, I. de Belle, C. Niemeyer, M. M. Gottardis, D. Mercola, and E. D. Adamson. 1997. Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int. J. Cancer. 72: 102-109.
19. Bligh, E. G., and W. J. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37: 911-917.
20. Porter, T. J., and C. Kent. 1990. Purification and characterization of choline/ethanolamine kinase from rat liver. J. Biol. Chem. 265: 414-422.
21. Zhu, L. J., and S.W. Altmann. 2005. mRNA and 18S-RNA coapplication-reverse transcription for quantitative gene expression analysis. Anal. Biochem. 345: 102-109.
22. Tsai, J. C., L. Liu, J. Zhang, K. C. Spokes, J. N. Topper, and W. C. Aird. 2001. Epidermal growth factor induces Egr-1 promoter activity in hepatocytes in vitro and in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 281: G1271-G1278.
23. Keeton, A. B., K. D. Bortoff, W. L. Bennett, J. L. Franklin, D. Y. Venable, and J. L. Messina. 2003. Insulin-regulated expression of Egr-1 and Krox20: dependence on ERK1/2 and interaction with p38 and PI3-kinase pathways. Endocrinology. 144: 5402-5410.
24. Hasan, R. N., S. Phukan, and S. Harada. 2003. Differential regulation of early growth response gene-1 expression by insulin and glucose in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 23: 988-993.
25. Revest, J-M., F. Di Blasi, P. Kitchener, F. Rougé-Pont, A. Desmedt, M. Turiault, F. Tronche, and P. V. Piazza. 2005. The MAPK pathway and Egr-1 mediate stress-related behavioral effects of glucocorticoids. Nat. Neurosci. 8: 664-672.
26. Ghosh, S., and M. Karin. 2002. Missing pieces in the NF-kappaB puzzle. Cell. 109 (Suppl): 81-96.
27. Dixon, R. M., and M. Tian. 1993. Phospholipid synthesis in the lymphomatous mouse liver studied by 31P nuclear magnetic resonance spectroscopy in vitro and by administration of 14C-radiolabelled compounds in vivo. Biochim. Biophys. Acta. 1181: 111-121.
28. Franks, S. E., A. C. Kuesel, N. W. Lutz, and W. E. Hull. 1996. 31P MRS of human tumor cells: effects of culture media and conditions on phospholipid metabolite concentrations. Anticancer Res. 16: 1365-1374.
29. Momchilova, A., T. Markovska, and R. Pankov. 1999. Ha-ras-transformation alters the metabolism of phosphatidylethanolamine and phosphatidylcholine in NIH 3T3 fibroblasts. Cell Biol. Int. 23: 603-610.
30. Ronen, S. M., E. Rushkin, and H. Degani. 1992. Lipid metabolism in large T47D human breast cancer spheroids: 31P- and 13C-NMR studies of choline and ethanolamine uptake. Biochim. Biophys. Acta. 1138: 203-212.
31. Li, Z., L. B. Agellon, T. M. Allen, M. Umeda, L. Jewell, A. Mason, and D. E. Vance. 2006. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab. 3: 321-331.
32. Steenbergen, R., T. S. Nanowski, R. Nelson, S. G. Young, and J. E. Vance. 2006. Phospholipid homeostasis in phosphatidylserine synthase-2-deficient mice. Biochim. Biophys. Acta. 1761: 313-323.
33. Zhang, R., L. Barker, D. Pinchev, J. Marshall, M. Rasamoelisolo, C. Smith, P. Kupchak, I. Kireeva, L. Ingratta, and G. Jackowski. 2004. Mining biomarkers in human sera using proteomic tools. Proteomics. 4: 244-256.
34. Iorio, E., D. Mezzanzanica, P. Alberti, F. Spadaro, C. Ramoni, S. D'Ascenzo, D. Millimaggi, A. Pavan, V. Dolo, S. Canevari, et al. 2005. Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 65: 9369-9376.
35. Bolognese, F., M. Pitarque-Marti, V. Lo Cicero, R. Mantovani, and J. A. Maier. 2006. Characterization of the human EDF-1 minimal promoter: involvement of NFY and Sp1 in the regulation of basal transcription. Gene. 374: 87-95.
36. Khachigian, L. M., V. Lindner, A. J. Williams, and T. Collins. 1996. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science. 271: 1427-1431.
37. Liu, C., E. Adamson, and D. Mercola. 1996. Transcription factor EGR-1 suppresses the growth and transformation of human HT-1080 fibrosarcoma cells by induction of transforming growth factor beta 1. Proc. Natl. Acad. Sci. USA. 93: 11831-11836.
38. Huang, R. P., T. Darland, D. Okamura, D. Mercola, and E. D. Adamson. 1994. Suppression of v-sis-dependent transformation by the transcription factor, Egr-1. Oncogene. 9: 1367-1377.
39. Huang, R. P., C. Liu, Y. Fan, D. Mercola, and E. D. Adamson. 1995. Egr-1 negatively regulates human tumor cell growth via the DNA-binding domain. Cancer Res. 55: 5054-5062.
40. Wenzel, K., K. Daskalow, F. Herse, S. Seitz, U. Zacharias, J. A. Schenk, H. Schulz, N. Hubner, B. Micheel, P. M. Schlag, et al. 2007. Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway. Biol. Chem. 388: 489-495.
41. Kim, C. G., B. H. Choi, S. W. Son, S. J. Yi, S. Y. Shin, and Y. H. Lee. 2007. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells. Cell. Signal. 19: 1290-1300.
42. Lee, C. H., Y-T. Jeon, S-H. Kim, and Y-S. Song. 2007. NF-kappaB as a potential molecular target for cancer therapy. Biofactors. 29: 19-35.
43. Cogswell, P. C., D. C. Guttridge, W. K. Funkhouser, and A. S. Baldwin, Jr. 2000. Selective activation of NF-kappaB subunits in human breast cancer: potential roles for NF-kappaB2/p52 and for Bcl-3. Oncogene. 19: 1123-1131.
44. Zhou, Y., S. Eppenberger-Castori, C. Marx, C. Yau, G. K. Scott, U. Eppenberger, and C. C. Benz. 2005. Activation of nuclear factor-κB (NFkB) identifies a high-risk subset of hormone-dependent breast cancers. Int. J. Biochem. Cell Biol. 37: 1130-1144.
45. Geymayer, S., and W. Doppler. 2000. Activation of NF-kappaB p50/p65 is regulated in the developing mammary gland and inhibits STAT5-mediated beta-casein gene expression. FASEB J. 14: 1159-1170.
46. Greten, F. R., L. Eckmann, T. F. Greten, J. M. Park, Z. W. Li, L. J. Egan, M. F. Kagnoff, and M. Karin. 2004. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell. 118: 285-296.
47. Farhana, L., M. I. Dawson, and J. A. Fontana. 2005. Apoptosis induction by a novel retinoid-related molecule requires nuclear factorkappaB activation. Cancer Res. 65: 4909-4917.
48. Ng, T. C., S. Grundfest, S. Vijayakumar, N. J. Baldwin, A. W. Majors, I. Karalis, T. F. Meaney, K. H. Shin, F. J. Thomas, and R. Tubbs. 1989. Therapeutic response of breast carcinoma monitored by 31P MRS in situ. Magn. Reson. Med. 10: 125-134.